Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy Williams

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Health Technology Assessment (Winchester, England)|February 19, 2019
Ten-year follow-up of a randomised trial of drainage, irrigation and fibrinolytic therapy (DRIFT) in infants with post-haemorrhagic ventricular dilatationKaren Luyt, Sally Jary, Charlotte Lea, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|July 6, 2020
Drainage, irrigation and fibrinolytic therapy (DRIFT) for posthaemorrhagic ventricular dilatation: 10-year follow-up of a randomised controlled trialKaren Luyt, Sally L Jary, Charlotte L Lea, et al.
Scientific Reports|March 19, 2021
Time spent outdoors in childhood is associated with reduced risk of myopia as an adultGareth Lingham, Seyhan Yazar, Robyn M Lucas, et al.
Ebiomedicine|April 13, 2023
A new polygenic score for refractive error improves detection of children at risk of high myopia but not the prediction of those at risk of myopic macular degenerationRosie Clark, Samantha Sze-Yee Lee, Ran Du, et al.
American Journal of Hematology|October 9, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Liana Gercheva, Cathy Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
JAMA Ophthalmology|April 8, 2021
Evaluation of Shared Genetic Susceptibility to High and Low Myopia and HyperopiaJ Willem L Tideman, Olavi Pärssinen, Annechien E G Haarman, et al.
British Journal of Haematology|July 18, 2015
Optimizing the management of patients with spinal myeloma diseaseSean Molloy, Maggie Lai, Guy Pratt, et al.
Genetic Epidemiology|September 10, 2016
When do myopia genes have their effect? Comparison of genetic risks between children and adultsJ Willem L Tideman, Qiao Fan, Jan Roelof Polling, et al.
International Journal of Epidemiology|June 7, 2017
Genetically low vitamin D concentrations and myopic refractive error: a Mendelian randomization studyGabriel Cuellar-Partida, Katie M Williams, Seyhan Yazar, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Health Technology Assessment (Winchester, England)|February 19, 2019
Ten-year follow-up of a randomised trial of drainage, irrigation and fibrinolytic therapy (DRIFT) in infants with post-haemorrhagic ventricular dilatationKaren Luyt, Sally Jary, Charlotte Lea, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|July 6, 2020
Drainage, irrigation and fibrinolytic therapy (DRIFT) for posthaemorrhagic ventricular dilatation: 10-year follow-up of a randomised controlled trialKaren Luyt, Sally L Jary, Charlotte L Lea, et al.
Scientific Reports|March 19, 2021
Time spent outdoors in childhood is associated with reduced risk of myopia as an adultGareth Lingham, Seyhan Yazar, Robyn M Lucas, et al.
Ebiomedicine|April 13, 2023
A new polygenic score for refractive error improves detection of children at risk of high myopia but not the prediction of those at risk of myopic macular degenerationRosie Clark, Samantha Sze-Yee Lee, Ran Du, et al.
American Journal of Hematology|October 9, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Liana Gercheva, Cathy Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
JAMA Ophthalmology|April 8, 2021
Evaluation of Shared Genetic Susceptibility to High and Low Myopia and HyperopiaJ Willem L Tideman, Olavi Pärssinen, Annechien E G Haarman, et al.
British Journal of Haematology|July 18, 2015
Optimizing the management of patients with spinal myeloma diseaseSean Molloy, Maggie Lai, Guy Pratt, et al.
Genetic Epidemiology|September 10, 2016
When do myopia genes have their effect? Comparison of genetic risks between children and adultsJ Willem L Tideman, Qiao Fan, Jan Roelof Polling, et al.
International Journal of Epidemiology|June 7, 2017
Genetically low vitamin D concentrations and myopic refractive error: a Mendelian randomization studyGabriel Cuellar-Partida, Katie M Williams, Seyhan Yazar, et al.
Pageof 14